Lynch, Holly Fernandez.
Holly Fernandez Lynch
Lynch, Holly Fernandez, 1981-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 4755304 (Personal)
Permalink: http://viaf.org/viaf/4755304
Preferred Forms
-
100 0 _
‡a
Holly Fernandez Lynch
-
100 1 _
‡a
Lynch, Holly Fernandez
-
100 1 _ ‡a Lynch, Holly Fernandez
-
100 1 _
‡a
Lynch, Holly Fernandez
-
100 1 _
‡a
Lynch, Holly Fernandez
-
100 1 _ ‡a Lynch, Holly Fernandez
-
100 1 _
‡a
Lynch, Holly Fernandez
-
100 1 _ ‡a Lynch, Holly Fernandez
-
100 1 _ ‡a Lynch, Holly Fernandez
-
100 1 _ ‡a Lynch, Holly Fernandez
-
100 1 _ ‡a Lynch, Holly Fernandez
-
100 1 _
‡a
Lynch, Holly Fernandez
‡d
1981-
-
100 1 _ ‡a Lynch, Holly Fernandez, ‡d 1981-
-
100 1 _
‡a
Lynch, Holly Fernandez,
‡d
1981-....
-
100 1 _ ‡a Lynch, Holly Fernandez.
4xx's: Alternate Name Forms (5)
5xx's: Related Names (1)
Works
| Title | Sources |
|---|---|
| Academic Advocacy: Opportunities to Influence Health and Science Policy Under U.S. Lobbying Law |
|
| Adding insult to injury: reluctance to engage in clinical research with at-risk groups further disenfranchises these populations |
|
| Addressing Financial Barriers to Enrollment in Clinical Trials |
|
| Association Between Financial Incentives and Participant Deception About Study Eligibility |
|
| Big data, health law, and bioethics |
|
| Biospecimens, Research Consent, and Distinguishing Cell Line Research |
|
| Compensating for research risk: permissible but not obligatory |
|
| Compliance with advance directives. Wrongful living and tort law incentives. |
|
| Conflicts of conscience in health care : an institutional compromise |
|
| Contraceptive Coverage and the Balance Between Conscience and Access |
|
| Designing development programs for non-traditional antibacterial agents |
|
| Differential payment to research participants in the same study: an ethical analysis |
|
| Discrimination at the doctor's office |
|
| Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research |
|
| Ethical evasion or happenstance and hubris? The U.S. Public Health Service STD Inoculation Study |
|
| Ethical Review and Methodologic Innovation in Phase 1 Cancer Trials-Reply |
|
| Evaluating the Quality of Research Ethics Review and Oversight: A Systematic Analysis of Quality Assessment Instruments |
|
| Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways |
|
| FDA in the twenty-first century / edited by Holly Fernandez Lynch and I. Glenn Cohen. - New York, 2015. |
|
| FDA in the twenty-first century : the challenges of regulating drugs and new technologies |
|
| Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission |
|
| Filthy Lucre or Fitting Offer? Understanding Worries About Payments to Research Participants |
|
| A Functional Approach to Assessing Consent for Biospecimen Research |
|
| Give them what they want? The permissibility of pediatric placebo-controlled trials under the best pharmaceuticals for children act |
|
| Human subjects research regulation, 2014: |
|
| Incorporating ethical principles into clinical research protocols: a tool for protocol writers and ethics committees |
|
| Informed Consent and the Role of the Treating Physician |
|
| Institutions as an ethical locus of research prioritisation |
|
| The Journey Toward Routinization: Triage Nursing and the Success of an Emergency Department-Based Routine HIV Testing Program |
|
| Law, religion, and health in the United States |
|
| The Legality of Biometric Screening of Professional Athletes |
|
| Making the case for completion bonuses in clinical trials |
|
| Minimal or reasonable? Considering the ethical threshold for research risks to nonconsenting bystanders and implications for nonconsenting participants |
|
| No Easy Answers in Allocating Unapproved COVID-19 Drugs Outside Clinical Trials |
|
| Nudging health : health law and behavioral economics |
|
| Offering Payment in Clinical Research: Enrolling Individuals With or at Risk for Opioid Use Disorder |
|
| On Scarcity and the Value of Clinical Trials. |
|
| Participant Protection in Phase 1 Pediatric Cancer Trials |
|
| Patient-Centered Outcomes Research: Stakeholder Perspectives and Ethical and Regulatory Oversight Issues |
|
| Patient-Engaged Research: Choosing the "Right" Patients to Avoid Pitfalls |
|
| Pay-to-Participate Trials and Vulnerabilities in Research Ethics Oversight |
|
| Paying Clinical Trial Participants: Legal Risks and Mitigation Strategies |
|
| Paying Participants in COVID-19 Trials |
|
| Paying Research Participants: Regulatory Uncertainty, Conceptual Confusion, and a Path Forward |
|
| Paying Research Participants: The Outsized Influence of "Undue Influence". |
|
| Prescription Requirements and Patient Autonomy: Considering an Over-the-Counter Default |
|
| Promoting Patient Interests in Implementing the Federal Right to Try Act |
|
| A Proposal to Address NFL Club Doctors' Conflicts of Interest and to Promote Player Trust |
|
| Protecting clinical trial participants and study integrity in the age of social media |
|
| Public Engagement, Notice-and-Comment Rulemaking, and the Common Rule |
|
| Reaping the Bounty of Publicly Available Clinical Trial Consent Forms |
|
| Regulating Research with Biospecimens under the Revised Common Rule |
|
| Regulatory flexibility for COVID-19 research |
|
| A Response to Commentaries |
|
| Revised 'Common Rule' Shapes Protections For Research Participants. |
|
| Right to Try Requests and Oncologists' Gatekeeping Obligations |
|
| The right to withdraw from controlled human infection studies: Justifications and avoidance |
|
| The rights and wrongs of intentional exposure research: contextualising the Guatemala STD inoculation study |
|
| The role of community engagement in addressing bystander risks in research: The case of a Zika virus controlled human infection study |
|
| Specimen science : ethics and policy implications |
|
| Streamlining review by accepting equivalence |
|
| Truth in Advertising: Disclosure of Participant Payment in Research Recruitment Materials |
|
| Unnecessary hesitancy on human vaccine tests-Response |
|
| Using Social Media as a Research Recruitment Tool: Ethical Issues and Recommendations |
|
| Waivers and Alterations of Research Informed Consent During the COVID-19 Pandemic |
|
| When clinical trials compete: prioritising study recruitment |
|
| When religious freedom clashes with access to care |
|
